Investors are closely watching the oral GLP-1 race as competition intensifies across the sector.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Eli Lilly’s Diabetes Pill Outperforms Oral Semaglutide in Phase 3 Trial
Investors are closely watching the oral GLP-1 race as competition intensifies across the sector.